country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

製品番号: HY-106698

Copy Link Print Information

Brovincamine

Brovincamine is an orally active slow Ca²⁺ channel blocker and vasodilator. Brovincamine reduces Ca²⁺ influx across the plasma membrane by blocking Ca²⁺ channels. Brovincamine inhibits catecholamine secretion, cholinergic function, autonomic parasympathetic nervous system activity, cerebrovascular resistance, and nerve stimulation-induced convulsive responses. Brovincamine induces cerebrovascular, coronary, and intracranial vasodilation, improves cerebral cortical microcirculation, enhances cerebral metabolic activity, and increases capillary clearance efficiency. Brovincamine can be used in research related to cerebral ischemic diseases, cardiac ischemic diseases, and normal-tension glaucoma.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

CAS 番号: 57475-17-9
分子式: C₂₁H₂₅BrN₂O₃
分子量:433.35

保管条件:

Please store the product under the recommended conditions in the Certificate of Analysis.

Brovincamine 構造式

CAS 番号: 57475-17-9

価格（税別）

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性

製品説明

Calcium Channel アイソフォーム固有の製品をすべて表示 :

体外実験

Brovincamine (30-100 μM; 10 min) inhibits Carbamoylcholine (HY-B1208)-induced (IC₅₀ 30 μM) and high K⁺-induced (IC₅₀ 100 μM) catecholamine secretion and calcium influx in cultured bovine adrenal chromaffin cells, and its inhibitory characteristics vary with extracellular Ca²⁺ concentration depending on the secretagogue^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

体内実験

Cardiovascular RegulationLocal Vascular Regulation

Cardiovascular Regulation

Brovincamine (6.4 mg/kg; intravenous injection; single administration) mildly inhibits the cardiovascular response to DMPP in spinal dogs^[2].
Brovincamine (2-4 mg/kg, intravenous injection; single/cumulative administration) slightly but dose-dependently inhibits ganglionic stimulant-induced tachycardia in spinal dogs^[2].

Local Vascular Regulation

Brovincamine (7.5 mg/kg/day; p.o.; daily administration; for 4 weeks) improves cortical cerebral capillary morphology in young adult rats and aged healthy rats by increasing the volume, length, and density of cortical cerebral capillaries while decreasing capillary diameter and intercapillary distance^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Mongrel dogs (either sex, weighing 6-12 kg, spinal model)^[2]
Dosage:

6.4 mg/kg
Administration:

i.v.; single dose
Result:

Slightly inhibited the increases in blood pressure and heart rate induced by i.v. DMPP.

Animal Model:

Mongrel dogs (either sex, weighing 6-12 kg, spinal model)^[2]
Dosage:

2 mg/kg; 4 mg/kg
Administration:

i.v.; single dose; cumulative
Result:

Induced a slight but stepwise inhibition of tachycardia elicited by DMPP, BCH, and AT II delivered to cardiac sympathetic ganglia.
Significantly reduced positive chronotropic responses to AT II.

Animal Model:

OFA (Sprague Dawley) (female; 12 months, 36 months)^[4]
Dosage:

7.5 mg/kg/day
Administration:

p.o.; daily; 4 weeks
Result:

Reduced capillary diameter from 3.20 μm to 2.97 μm in 12-month-old rats.
Increased capillary volume fraction from 3.62% to 4.46% in 12-month-old rats.
Reduced mean intercapillary distance from 30.90 μm to 27.79 μm in 12-month-old rats.
Increased capillary length per unit cortex from 54.87 cm/mm³ to 69.03 cm/mm³ in 12-month-old rats.
Increased number of capillaries per measuring field from 20 to 23 in 12-month-old rats.
Reduced capillary diameter from 3.29 μm to 3.09 μm in 36-month-old rats.
Increased capillary volume fraction from 3.67% to 4.45% in 36-month-old rats.
Reduced mean intercapillary distance from 31.04 μm to 28.78 μm in 36-month-old rats.
Increased capillary length per unit cortex from 50.77 cm/mm³ to 71.15 cm/mm³ in 36-month-old rats.
Increased number of capillaries per measuring field from 19 to 23 in 36-month-old rats.

Related Protocols :

化学情報

CAS 番号 57475-17-9
分子量 433.35
分子式 C₂₁H₂₅BrN₂O₃
SMILES

C(C)[C@]12[C@]3(C=4N(C=5C(C4CCN3CCC1)=CC=C(Br)C5)[C@](C(OC)=O)(O)C2)[H]
輸送条件

Room temperature in continental US; may vary elsewhere.
保管条件

Please store the product under the recommended conditions in the Certificate of Analysis.

純度とドキュメンテーション

取扱説明書 (2659 KB)

参考文献

[1]. Morita K, et al. Inhibitory action of brovincamine on catecholamine secretion from cultured bovine adrenal medullary cells: possible relation to its blocking action on Ca2+ channels. Biochem Pharmacol. 1991 Jun 21;42(1):190-2.

[2]. Kushiku K, et al. Effects of brovincamine on the autonomic nervous function in the dog and rat. Journal of pharmacobio-dynamics. 1984 Mar;7(3):177-85.

[3]. Sawada A, et al. Prevention of visual field defect progression with brovincamine in eyes with normal-tension glaucoma. Ophthalmology. 1996 Feb;103(2):283-8.

[4]. Meier-Ruge W, et al. Effects of brovincamine on the stereological parameters of corticocerebral capillaries. Life sciences. 1987 Mar 09;40(10):943-9.

Calculators

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

お問い合わせ在庫あり

Other size

お問い合わせ